Running marathons or endurance races is often seen as a hallmark of peak fitness. However, a groundbreaking new study led by Inova oncologist Tim Cannon, MD, Sheridan Director, Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, reveals a surprising prevalence of precancerous colon growths among extreme runners. Recently featured in The New York Times, the study opens new discussions about screening opportunities.
Article links:
Study at a glanceInova’s incidental lung nodule program has shown a 76% reduction in time…
Catherine Wymer, PharmD, is a senior clinical pharmacist at Inova 360° Concierge Medicine. As a…
Multidisciplinary pulmonary expertise supports diagnostic evaluation, treatment planning and longitudinal care Advanced lung disease and…
Heart failure is a major focus for Inova Schar Heart and Vascular’s care transformation efforts.…
TETON pivotal studies meet primary end point In two landmark phase 3 trials, nebulized Tyvaso®…
Leesburg, VA — Inova Blood Donor Services (IBDS) invites the Loudoun County community to roll…